Conditions: Type 2 Diabetes
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 972
Healthy volunteers: no

Brief summary:
The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on TZD alone. The safety of this treatment will also be studied

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: Dapagliflozin intervention 2: Dapagliflozin intervention 3: Placebo matching Dapagliflozin intervention 4: Thiazolidinedione (Pioglitazone)
Intervention descriptions: intervention 1: Tablets, Oral, 5.0 mg, once daily, up to 48 weeks intervention 2: Tablets, Oral, 10.0 mg, once daily, up to 48 weeks intervention 3: Tablets, Oral, 0 mg, once daily, up to 48 weeks intervention 4: Tablets, ≥ 30 mg, Once daily, up to 48 weeks

Protocol document: